Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seyma Büyücek

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Neoplasia (New York, N.Y.)|June 24, 2025
Prognostic role of high MTAP expression is reversed by the ERG status in prostate cancer treated by radical prostatectomyNatalia Gorbokon, Seyma Büyücek, Henning Plage, et al.
Annals of Diagnostic Pathology|February 10, 2025
Brachyury expression is highly specific for chordoma: A tissue microarray study involving 14,976 cancers from 135 different tumor types and subtypesPiero Caneve, Nina Schraps, Katharina Möller, et al.
Frontiers in Oncology|May 20, 2026
Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumorsViktoria Chirico, Niklas Jahn, Seyma Büyücek, et al.
Biomedicines|July 29, 2025
Glucocorticoid Receptor (GR) Expression in Human Tumors: A Tissue Microarray Study on More than 14,000 TumorsMaria Christina Tsourlakis, Simon Kind, Sebastian Dwertmann Rico, et al.
Cancers|July 13, 2024
Stimulator of Interferon Genes Protein (STING) Expression in Cancer Cells: A Tissue Microarray Study Evaluating More than 18,000 Tumors from 139 Different Tumor EntitiesAnne Menz, Julia Zerneke, Florian Viehweger, et al.
Experimental and Molecular Pathology|November 26, 2025
Prevalence and clinical significance of CBP deficiency and disturbed CBP expression in human cancerVictoria Chirico, Tabea Lenkeit, Seyma Büyücek, et al.
Acta Oncologica (Stockholm, Sweden)|December 2, 2025
L1CAM/CD171 expression in human tumors and its association with tumor phenotypeSeyma Büyücek, Magalie Lurati, Katharina Möller, et al.
Plos One|April 2, 2025
Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumorsSeyma Büyücek, Florian Viehweger, Viktor Reiswich, et al.
Diagnostics (Basel, Switzerland)|August 14, 2025
HMGB1 Deficiency Occurs in a Broad Range of Human Cancers and Is Often Associated with Unfavorable Tumor PhenotypeViktoria Chirico, Hena Sharifi, Maria Christina Tsourlakis, et al.
Biomarker Research|December 10, 2024
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samplesSeyma Büyücek, Nina Schraps, Anne Menz, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Neoplasia (New York, N.Y.)|June 24, 2025
Prognostic role of high MTAP expression is reversed by the ERG status in prostate cancer treated by radical prostatectomyNatalia Gorbokon, Seyma Büyücek, Henning Plage, et al.
Annals of Diagnostic Pathology|February 10, 2025
Brachyury expression is highly specific for chordoma: A tissue microarray study involving 14,976 cancers from 135 different tumor types and subtypesPiero Caneve, Nina Schraps, Katharina Möller, et al.
Frontiers in Oncology|May 20, 2026
Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumorsViktoria Chirico, Niklas Jahn, Seyma Büyücek, et al.
Biomedicines|July 29, 2025
Glucocorticoid Receptor (GR) Expression in Human Tumors: A Tissue Microarray Study on More than 14,000 TumorsMaria Christina Tsourlakis, Simon Kind, Sebastian Dwertmann Rico, et al.
Cancers|July 13, 2024
Stimulator of Interferon Genes Protein (STING) Expression in Cancer Cells: A Tissue Microarray Study Evaluating More than 18,000 Tumors from 139 Different Tumor EntitiesAnne Menz, Julia Zerneke, Florian Viehweger, et al.
Experimental and Molecular Pathology|November 26, 2025
Prevalence and clinical significance of CBP deficiency and disturbed CBP expression in human cancerVictoria Chirico, Tabea Lenkeit, Seyma Büyücek, et al.
Acta Oncologica (Stockholm, Sweden)|December 2, 2025
L1CAM/CD171 expression in human tumors and its association with tumor phenotypeSeyma Büyücek, Magalie Lurati, Katharina Möller, et al.
Plos One|April 2, 2025
Reduced occludin expression is related to unfavorable tumor phenotype and poor prognosis in many different tumor types: A tissue microarray study on 16,870 tumorsSeyma Büyücek, Florian Viehweger, Viktor Reiswich, et al.
Diagnostics (Basel, Switzerland)|August 14, 2025
HMGB1 Deficiency Occurs in a Broad Range of Human Cancers and Is Often Associated with Unfavorable Tumor PhenotypeViktoria Chirico, Hena Sharifi, Maria Christina Tsourlakis, et al.
Biomarker Research|December 10, 2024
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samplesSeyma Büyücek, Nina Schraps, Anne Menz, et al.
Pageof 2